Staurosporine

Catalog No.S1421 Synonyms: CGP 41251

Staurosporine Chemical Structure

Molecular Weight(MW): 466.53

Staurosporine is a potent PKC inhibitor for PKCα, PKCγ and PKCη with IC50 of 2 nM, 5 nM and 4 nM, less potent to PKCδ (20 nM), PKCε (73 nM) and little active to PKCζ (1086 nM) in cell-free assays. Also shows inhibitory activities on other kinases, such as PKA, PKG, S6K, CaMKII, etc. Phase 3.

Size Price Stock Quantity  
USD 270 In stock

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

3 Customer Reviews

  • Intracellular concentration of HSF1-phosphoserine 326, total HSF1, S6 kinase-phosphothreonine-389, total S6 kinase and β-actin, without or with heat shock in HeLa cells pretreated with mTOR inhibitors rapamycin (30 nM) and KU0063794 (2 uM) and kinase inhibitor staurosporine (100 nM) for 2 hr. Relative levels of HSF1-phosphoserine 326 in cells after the various treatments were determined by densitometric analysis of X-ray films, normalized to untreated cells (lane 1), and are indicated below the representation of the immunoblots.

    PLoS One 2012 7(6), e39679. Staurosporine purchased from Selleck.

    J Biomol Screen 2013 18(4), 388-99. Staurosporine purchased from Selleck.

  • J Biomol Screen 2013 18(4), 388-99. Staurosporine purchased from Selleck.

Purity & Quality Control

Choose Selective PKC Inhibitors

Click to view more

Notes:

2. For more details, such as half maximal inhibitory concentrations (IC50s) and working concentrations of each inhibitor, please click on the link of the inhibitor of interest.
3. "+" indicates inhibitory effect. Increased inhibition is marked by a higher "+" designation.
4. Orange "√" refers to compounds which do inhibitory effects on the related isoform, but without specific value.

Biological Activity

Description Staurosporine is a potent PKC inhibitor for PKCα, PKCγ and PKCη with IC50 of 2 nM, 5 nM and 4 nM, less potent to PKCδ (20 nM), PKCε (73 nM) and little active to PKCζ (1086 nM) in cell-free assays. Also shows inhibitory activities on other kinases, such as PKA, PKG, S6K, CaMKII, etc. Phase 3.
Targets
PKCα [1]
(Cell-free assay)
c-Fgr [2] phosphorylase kinase [2] PKCη [1]
(Cell-free assay)
PKCγ [1]
(Cell-free assay)
2 nM 2 nM 3 nM 4 nM 5 nM
In vitro

Staurosporine, a microbial alkaloid, significantly inhibits protein kinase C from rat brain with IC50 of 2.7 nM. Staurosporine displays strong inhibitory effect against HeLa S3 cells with IC50 of 4 nM. [1] Staurosporine also inhibits a variety of other protein kinases, including PKA, PKG, phosphorylase kinase, S6 kinase, Myosin light chain kinase (MLCK), CAM PKII, cdc2, v-Src, Lyn, c-Fgr, and Syk with IC50 of 15 nM, 18 nM, 3 nM, 5 nM, 21 nM, 20 nM, 9 nM, 6 nM, 20 nM, 2 nM, and 16 nM, respectively. [2] Staurosporine (1 μM) induces >90% apoptosis in PC12 cells. Consistently, Staurosporine treatment induces a rapid and prolonged elevation of intracellular free calcium levels [Ca2+]i, accumulation of mitochondrial reactive oxygen species (ROS), and subsequent mitochondrial dysfunction. [3] The apoptosis of MCF7 cells induced by Staurosporine can be enhanced by the expression of functional caspase-3 via caspase-8 activation and Bid cleavage. [4] Staurosporine treatment at 1 μM only partially inhibits IL-3-stimulated Bcl2 phosphorylation but completely blocks PKC-mediated Bcl2 phosphorylation. [5] Staurosporine induces apoptosis of human foreskin fibroblasts AG-1518, depending on the lysosomal cathepsins D mediated cytochrome c release and caspase activation. [6] In addition to activating the classical mitochondrial apoptosis pathway, Staurosporine triggers a novel intrinsic apoptosis pathway, relying on the activation of caspase-9 in the absence of Apaf-1. [7]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
human HeLa cells NIjzNHlEgXSxdH;4bYPDqGG|c3H5 NELXZlg1QCCq MmGyR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gTIVN[SClZXzsd{Bi\nSncjC0PEBpenNiYomgUXRVKGG|c3H5MEBKSzVyPUTlMVA3KM7:TT6= NVrpZXZDOjF|OEixPVE>
human colon cancer cell line (LoVo cells) MkXJVJJwdGmoZYLheIlwdiCjc4PhfS=> NHLWd4tCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIHPvcI9vKGOjbnPldkBk\WyuIHzpcoUhMEyxVn:gZ4VtdHNrIIXzbY5oKE2WVDDhd5NigSxiSVO1NF0xNjByMTFOwG0v NFj5PYUyOTV7MUWwOS=>
human LoVo cells Mn7kVJJwdGmoZYLheIlwdiCjc4PhfS=> NIfUepA1QCC2bzC3NkBp NIDVblRCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIFzvWo8h[2WubIOgZYZ1\XJiNEigeI8hPzJiaILzJIJ6KE2WVDDhd5NigQ>? NU\xXGhWOjJzOEK5Nlk>
P19 cells M1WxRWZ2dmO2aX;uJIF{e2G7 M3HDd2lvcGmkaYTpc44hd2ZiUHzheIVt\XRvZHXybZZm\CCpcn;3eIgh\mGldH;yJJJm[2WydH;yJIlvKFBzOTDj[YxteyxiSVO1NF0xNjByMjFOwG0v NVvYWJU6OTV5N{G0NVk>
human BJ cells M{npRWN6fG:2b4jpZ:Kh[XO|YYm= NHLKN4o4OiCq NHnjWIpEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBDUiClZXzsd{Bi\nSncjC3NkBpenNiYomgR4Ft[2WrbjDBUUBie3OjeTygTWM2OD1yLkCwNkDPxE1w MYmyNlkzOTB6MR?=
human HT-29 cells MnzWSpVv[3Srb36gZZN{[Xl? MVWyJIg> M{frT2Vn\mWldDDvckBucXSxY3jvcoRzcWGuIH3lcYJz[W6nIIDveIVvfGmjbDDpckBpfW2jbjDIWE0zQSClZXzsd{Bi\nSncjCyJIhzeyC3c3nu[{BLSy1zIIP0ZYlvcW6pIHL5JIZtfW:{ZYPj[Y5k\SCjc4PhfS=> NWOzXGlWOjF2MkizO|U>
human A549 cells NWDhZVNPS3m2b4TvfIlkyqCjc4PhfS=> M2HrS|czKGh? NHLXe|JEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBCPTR7IHPlcIx{KGGodHXyJFczKGi{czDifUB{fWyob4Loc4RidWmwZTDCJI1mfGixZB?= NVXkO5RCOTh2OES3O|U>
human HT-29 cells NVO3cnJyTnWwY4Tpc44h[XO|YYm= MXnJcohq[mm2aX;uJI9nKG2rdH;jbI9v\HKrYXygcYVu[nKjbnWgdI91\W62aXHsJIlvKGi3bXHuJGhVNTJ7IHPlcIx{KHW|aX7nJGpEOSCmeXWgd5RicW6rbnegZpkh\my3b4Lld4NmdmOnIIDsZZRmKHKnYXTldkBie3OjeTygTWM2OD1{LkWgcm0> NGm2cmgzOTVzM{K5Ny=>
human HT-29 cells MYnGeY5kfGmxbjDhd5NigQ>? NYD0O5VSOiCq MojPTY5lfWO2aX;uJI9nKGGyb4D0c5NqeyCrbjDoeY1idiCKVD2yPUBk\WyuczDhd5Nme3OnZDDy[YR2[3Srb36gc4YhdWm2b3Poc45lemmjbDDt[Y1jemGwZTDwc5RmdnSrYXygZYZ1\XJiMjDodpMh[nlidYPpcochUkNzIIP0ZYlvcW6pIHL5JIZtfW:{ZYPj[Y5k\SClZXzsMYJie2WmIHHzd4F6NCCHQ{WwQVIvPiCwTT6= MnyxNlE6PzNzMEG=
Sf9 cells NH3zXXZHfW6ldHnvckBie3OjeR?= MnjZTY5pcWKrdHnvckBw\iCqdX3hckBUgWtiZYjwdoV{e2WmIHnuJHNnQSClZXzsd{whUUN3ME2zJI5ONg>? MlnUNVg5OjN5OES=
human HUVEC NHHvNI9Rem:uaX\ldoF1cW:wIHHzd4F6 M{TyTVQ5KHSxIEeyJIg> MULBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKEiXVlXDJIFnfGW{IES4JJRwKDd{IHjyd{BjgSCPVGSgZZN{[Xl? Mmn4NlIyQDJ7Mkm=
P19 cells NF3z[pBHfW6ldHnvckBie3OjeR?= MV3Jcohq[mm2aX;uJI9nKFC{b4TlbY4hU2mwYYPlJGEhcW5iUEG5JINmdGy|LDDJR|UxRTRibl2u MV[xOVc4OTRzOR?=
Sf9 cells MojiSpVv[3Srb36gZZN{[Xl? M2fhTGlvcGmkaYTpc44hd2ZiaIXtZY4hTnmwIHX4dJJme3OnZDDpckBU\jliY3XscJMh[W[2ZYKgNUBucW5iYomgSWxKW0FiaX6gdJJme2WwY3Wgc4YhOSC3bX;sM2whSVSS MVmxO|MyPTh3Mx?=
Sf21 cells MWPGeY5kfGmxbjDhd5NigQ>? M4HjVWlvcGmkaYTpc44hd2ZiSlHLN{BmgHC{ZYPz[YQhcW5iU3[yNUBk\WyuczygTWM2OD14IH7NMi=> MnrONVcxQDhyNUm=
human colon carcinoma cell line HCT116 MWHGeY5kfGmxbjDhd5NigQ>? NYPxPYVxS2:wY3XueJJifGmxbjDy[ZF2cXKnZDDmc5Ih\3Kxd4ToJIlvcGmkaYTpc44hd2ZiaIXtZY4h[2:ub36gZ4Fz[2mwb33hJINmdGxibHnu[UBJS1RzMU[sJGlEPTB;NjDuUU4> NVP5fo9FOTV3M{ezOFU>
human ST486 cells M1\lV3Bzd2yrZnXyZZRqd25iYYPzZZk> M3HzTFQ5KHSxIEeyJIg> M2\KTGFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iU2S0PFYh[2WubIOgZYZ1\XJiNEigeI8hPzJiaILzJIJ6KE2WVDDhd5NigSxiSVO1NF04KG6PLh?= NGrifY0zOjF6MkmyPS=>
human MDA-MB-231 cells Mm[xR5l1d3SxeHnjxsBie3OjeR?= MlPnO|IhcA>? M2TxbGN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJG1FSS2PQj2yN|Eh[2WubIOgZYZ1\XJiN{KgbJJ{KGK7IIP1cIZwemixZHHtbY5mKEJibXX0bI9lNCCJSUWwQVcvOSCwTT6= NUPIOVRpOTh2OES3O|U>
P19 cells NGG4dZFHfW6ldHnvckBie3OjeR?= NHjpdo1KdmirYnn0bY9vKG:oIFP5Z4xqdi2mZYDlcoRmdnRia3nuZZNmKDFiaX6gVFE6KGOnbHzzMEBKSzVyPUigcm0v MlP2NVU4PzF2MUm=
human DLD1 cells M{\aNXBzd2yrZnXyZZRqd25iYYPzZZk> NWnLfJhiPDhvN{KgbC=> NF;Dd2hCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIFTMSFEh[2WubIOgZYZ1\XJiNEigeI8hPzJiaILzJIJ6KE2WVDDhd5NigSxiSVO1NF06KG6PLh?= MWiyNlE5Ojl{OR?=
insect cells MYDGeY5kfGmxbjDhd5NigQ>? MmW1TY5pcWKrdHnvckBw\iCqdX3hckBz\WOxbXLpcoFvfCCSaX2xJIV5eHKnc4Pl[EBqdiCrboPlZ5Qh[2WubIOgZpkhUFSURjygTWM2OD1zMDDuUU4> NHXWTpkyQTF5OUC3Oi=>
V79 MZ cells NHS1doVHfW6ldHnvckBie3OjeR?= MXzJcohq[mm2aX;uJI9nKGi3bXHuJIFt\G:|dHXyc45mKHO7boToZZNmKGW6cILld5Nm\CCrbjDWO|khVVpiY3XscJMh[XO|ZYPz[YQh[XNiaX7obYJqfGmxbjDv[kBidGSxc4Tldo9v\SC|eX70bIV{cXNuIFnDOVA:OTFibl2u M4TNbVI1PDJ{NUG5
P19 cells NXyy[ZA4TnWwY4Tpc44h[XO|YYm= MVjJcohq[mm2aX;uJI9nKF[jc3P1cIFzKGWwZH;0bIVtcWGuIHfyc5d1cCCoYXP0c5IhemWlZYD0c5IhcW5iUEG5JINmdGy|LDDJR|UxRTF2IH7NMi=> MXexOVc4OTRzOR?=
Sf9 cells MXfGeY5kfGmxbjDhd5NigQ>? Mlq0NlAhdWmwcx?= M{ThR2lvcGmkaYTpc44hd2ZiaIXtZY4hTnmwIHX4dJJme3OnZDDpckBU\jliY3XscJMh[W[2ZYKgNlAhdWmwczDifUBGVEmVQTDpckBxemW|ZX7j[UBw\iBzIIXtc4wwVCCDVGCsJGlEPTB;MUWgcm0v Mon6NVc{OTV6NUO=
human PBMC NHLkcXNHfW6ldHnvckBie3OjeR?= NGjtTpozPCCq NIH5b2NUfXCycnXzd4lwdiCxZjDJUFIheHKxZIXjeIlwdiCrbjDoeY1idiCSQl3DJIFnfGW{IEK0JIhzeyCkeTDFUGlUSSxiSVO1NF0yPiCwTT6= MUOxPFU5PTB2Nh?=
human A549 cells NHnRUG5EgXSxdH;4bYPDqGG|c3H5 MYq0PEBp MmW5R5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gRVU1QSClZXzsd{Bi\nSncjC0PEBpenNiYomgUXRVKGG|c3H5JEwhUUN3ME2yNEBvVS5? M3PWVFI2QDJ3OUO0
human CEM cells M3XwOmN6fG:2b4jpZ:Kh[XO|YYm= Ml:4O|IhcA>? MlvRR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gR2VOKGOnbHzzJIFnfGW{IEeyJIhzeyCkeTDDZYxk\WmwIFHNJIF{e2G7LDDJR|UxRTJ|IH7NMi=> NX:yZoJDOjJ7MkGwPFE>
human HeLa cells NYLp[GRkS3m2b4TvfIlkyqCjc4PhfS=> MoWxOFghcA>? NXLEcZhUS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hUGWOYTDj[YxteyCjZoTldkA1QCCqcoOgZpkhVVSWIHHzd4F6NCCLQ{WwQVI2KG6PLh?= Ml;aNlU5OjV7M{S=
human PC3 cells MXrDfZRwfG:6aXRCpIF{e2G7 MmnvOFghcA>? M2L4XWN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJHBEOyClZXzsd{Bi\nSncjC0PEBpenNiYomgUXRVKGG|c3H5JEwhUUN3ME2zNUBvVS5? NFqyfZIzPTh{NUmzOC=>
human SF268 cells MVzDfZRwfG:6aXRCpIF{e2G7 NVPZOm1XPDhiaB?= NWrlWFRHS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hW0Z{NkigZ4VtdHNiYX\0[ZIhPDhiaILzJIJ6KFOUQjDhd5NigSxiR1m1NF01PCCwTT6= M3THUVIyPTF|Mkm0
human MCF7 cells MlrmR5l1d3SxeHnjxsBie3OjeR?= MX[0PEBp MmjzR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gUWNHPyClZXzsd{Bi\nSncjC0PEBpenNiYomgUXRVKGG|c3H5MEBKSzVyPUWwJI5ONg>? MnntNlE{QDhzOUG=
HEK293 cells MU\DfZRwfG:6aXRCpIF{e2G7 M{nCPVczKGh? MWXDfZRwfG:6aXPpeJkh[WejaX7zeEBJTUt{OUOgZ4VtdHNiYX\0[ZIhPzJiaILzJIJ6KEOnbHzUbZRmekeubzDhd5NigSxiSVO1NF02PiCwTT6= NV\meplEOjR5NkOyOlI>
HUE cells NEK3TplHfW6ldHnvckBie3OjeR?= MoP1PVAhdWmwcx?= M2nS[WlvcGmkaYTpc44hd2ZiVlXHSnIzKGmwIFjVSUBk\WyuczDhd5Nme3OnZDDhd{BqdmirYnn0bY9vKG:oIG\FS2YucW6mdXPl[EBifXSxcHjvd5Bpd3K7bHH0bY9vKHS{ZXH0[YQh\m:{IEmwJI1qdnNiYnXmc5JmKF[HR1[gZ4hidGynbnflJIJ6KEWOSWPBMEBKSzVyPUewJI5ONg>? MYGyNFE4ODF4Mx?=
human A431 cells M13WcGN6fG:2b4jpZ:Kh[XO|YYm= NYn2TIE2OjRiIHi= MU\DfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDBOFMyKGOnbHzzJIFnfGW{IEK0JIhzeyC3c3nu[{BCdm6neHnuJHZmTkmWQz;wdo9xcWSrdX2gbY9lcWSnIIP0ZYlvcW6pIHL5JG1VXCCjc4PhfUwhUUN3ME23NEBvVS5? NWnUNJdQOjJ3NEGwOVE>
human Jurkat cells MkPWVJJwdGmoZYLheIlwdiCjc4PhfS=> NUDpbJdjSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBLSUt|IHX4dJJme3OrbnegTWwzNXO2aX31cIF1\WRiaIXtZY4hUnW{a3H0JINmdGy|LDDJR|UxRTdzIH7NMi=> MkXhNVk1Ojd{MEO=
HEK293 cells NGe4RnlHfW6ldHnvckBie3OjeR?= M1XRdWlvcGmkaYTpc44hd2ZiSVytPEBz\WynYYPlJIJ6KEiHS{K5N{Bk\WyuczDlfJBz\XO|aX7nJHBMSy2kZYThNkwhUUN3ME23O{BvVS5? NGGxZoEyPTd5MUSxPS=>
human KE-97 cells M{P3NWN6fG:2b4jpZ:Kh[XO|YYm= MXq3NkBp MoHFR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gT2UuQTdiY3XscJMh[W[2ZYKgO|IhcHK|IHL5JGNmdGyWaYTy[U1IdG9ibIXtbY5me2OnboSgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NE4yOyEQvF2u NX\HSGdsOjR|MkiyPFM>
human CHOK1 cells NH2wbo1EgXSxdH;4bYPDqGG|c3H5 MkTxOFghcA>? MkW2R5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gR2hQUzFiY3XscJMh[W[2ZYKgOFghcHK|IHL5JHNTSiCjc4Phfg+9lCCLQ{WwQVAvOTNizszNMi=> M37NfVIyPTF|Mkm0
mouse NIH/3T3 cells MW\DfZRwfG:6aXRCpIF{e2G7 Ml\NPVYhcA>? MWTDfZRwfG:6aXPpeJkh[WejaX7zeEBud3W|ZTDOTWgwO1R|IHPlcIx{KGGodHXyJFk3KGi{czDifUBUWkJiYYPzZZktKEmFNUC9NE4zKM7:TT6= NFW5Z|EzPDN4MUWyNS=>
human A2780 cells MlXuR5l1d3SxeHnjxsBie3OjeR?= MV65OkBp MmG1R5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gRVI4QDBiY3XscJMh[W[2ZYKgPVYhcHK|IHL5JHNTSiCjc4PhfUwhUUN3ME2wMlIh|ryPLh?= M3zGWVI1OzZzNUKx
human 8505C cells M3XZS2N6fG:2b4jpZ:Kh[XO|YYm= NVHUUWxCQTZiaB?= MmTnR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gPFUxPUNiY3XscJMh[W[2ZYKgPVYhcHK|IHL5JHNTSiCjc4PhfUwhUUN3ME2wMlIh|ryPLh?= MlPFNlQ{PjF3MkG=
human 518A2 cells MlTPR5l1d3SxeHnjxsBie3OjeR?= NHPtNHU6PiCq NYDLO3ZUS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hPTF6QUKgZ4VtdHNiYX\0[ZIhQTZiaILzJIJ6KFOUQjDhd5Nige,:jDDJR|UxRTBwMjFOwG0v NWjCNZVTOjR|NkG1NlE>
human HuH7 cells NHT0Z|ZEgXSxdH;4bYPDqGG|c3H5 MnfJO|IhcA>? NIfXSVJEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBJfUh5IHPlcIx{KGGodHXyJFczKGi{czDifUBE\WyuVHn0doUuT2yxIHz1cYlv\XOlZX70JINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVAvOjNizszNMi=> MYCyOFMzQDJ6Mx?=
FL5.12-Akt1 cells M{HlSXBzd2yrZnXyZZRqd25iYYPzZZk> NFnTTFVCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JGZNPS5zMj3Bb5QyKGOnbHzzJIJ6KE2WVDDhd5NigSxiSVO1NF0xNjJ7IN88UU4> NV;iN|ZKOTZ2MEO2NlY>
human MiaPaCa-2 cells MWrQdo9tcW[ncnH0bY9vKGG|c3H5 Ml7XRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6|dDDoeY1idiCPaXHQZWNiNTJiY3XscJMtKEmFNUC9NE4{PyEQvF2u NH7xUWcyPjRzM{e4NC=>
human BGC823 cells MXLDfZRwfG:6aXRCpIF{e2G7 NXOwbWtoPzJiaB?= MVXDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDCS2M5OjNiY3XscJMh[W[2ZYKgO|IhcHK|IHL5JGNmdGyWaYTy[U1IdG9ibIXtbY5me2OnboSgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NE4{QCEQvF2u Mlj6NlQ{Ojh{OEO=
human MCF7 cells NFjxenBEgXSxdH;4bYPDqGG|c3H5 MXu5OkBp Ml7pR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gUWNHPyClZXzsd{Bi\nSncjC5OkBpenNiYomgV3JDKGG|c3H5MEBKSzVyPUCuOEDPxE1w M2HUZlI1OzZzNUKx
human A549 cells MYPDfZRwfG:6aXRCpIF{e2G7 M2DBcFk3KGh? M{XsdGN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJGE2PDliY3XscJMh[W[2ZYKgPVYhcHK|IHL5JHNTSiCjc4PhfUwhUUN3ME2wMlYh|ryPLh?= M3;qclI1OzZzNUKx
HEK293 cells Ml;pR5l1d3SxeHnjxsBie3OjeR?= MmHFR5l1d3SxeHnjbZR6KGGpYXnud5QhUEWNMkmzJINmdGy|LDDFR|UxRTJizszNMi=> M3fNSVI2OzF4M{G3
human Raji cells  M4DNZWN6fG:2b4jpZ:Kh[XO|YYm= MknFR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gVoFrcSClZXzsd{whTUN3ME2yJO69VS5? MXSyOVMyPjNzNx?=
human HepG2 cells NYG0fpZOS3m2b4TvfIlkyqCjc4PhfS=> MWjDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDI[ZBIOiClZXzsd{whTUN3ME2yJO69VS5? NUnENYFHOjV|MU[zNVc>
human BJ cells MmOwR5l1d3SxeHnjxsBie3OjeR?= M1jQTWN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJGJLKGOnbHzzMEBGSzVyPUKg{txONg>? MXGyOVMyPjNzNx?=
human U937 cells NUfXNJNbS3m2b4TvfIlkyqCjc4PhfS=> NIjsUoNEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBWQTN5IHPlcIx{NCCLQ{WwQVIh|ryPLh?= MnryNVcxQDhyNke=

... Click to View More Cell Line Experimental Data

In vivo In the gerbil and rat ischemia models, Staurosporine pretreatment (0.1-10 ng) before ischemia prevents neuronal damage in a dose-dependent manner, suggesting the involvement of PKC in CAl pyramidal cell death after ischemia. [8]

Protocol

Kinase Assay:

[1]

+ Expand

Enzyme assay and binding assay:

Protein kinase C is assayed in a reaction mixture (0.25 mL) containing 5 μmol of Tris/HCl, pH 7.5, 2.5 μmol of magnesium acetate, 50 μg of histone II S, 20 μg of phosphatidylserine, 0.88 μg of diolein, 125 nmol of CaCl2, 1.25 nmol of [γ-32]ATP (5-10 × 104 cpm/nmol) and 5 μg of partially purified enzyme. The binding of [3H]PDBu to protein kinase C is determined: Reaction mixture (200 μL contained 4 μmo1 of Tris/malate, pH 6.8, 20 μmol of KCl, 30 nmol of CaC12, 20 μg of phosphatidylserine, 5 μg of partially purified protein kinase C, 0.5% (final concentration) of DMSO,10 pmol of [3H]PDBu (l-3 × 104 cpm/pmol) and 10 μL of various amounts of Staurosporine.
Cell Research:

[3]

+ Expand
  • Cell lines: PC12
  • Concentrations: Dissolved in DMSO, final concentration 1 μM
  • Incubation Time: ~32 hours
  • Method:

    Cells are exposed to Staurosporine for ~32 hours. Cells are fixed in 4% paraformaldehyde and stained with the DNA-binding dye Hoechst 33342. Cells are visualized under epifluorescence illumination, and the percentage of apoptotic cells (cells with condensed and fragmented DNA) is determined.


    (Only for Reference)
Animal Research:

[8]

+ Expand
  • Animal Models: Male Mongolian gerbils or male Wistar rats subjected to transient ischemia
  • Formulation: Dissolved in DMSO, and diluted in saline
  • Dosages: ~10 ng
  • Administration: Stereotaxically administered into the bilateral CAl subfield of the hippocampus
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 4 mg/mL (8.57 mM)
Water <1 mg/mL
Ethanol <1 mg/mL
In vivo

* 1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 466.53
Formula

C28H26N4O3

CAS No. 62996-74-1
Storage powder
in solvent
Synonyms CGP 41251

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT00301938 Completed Accelerated Phase Chronic Myelogenous Leukemia|Adult Acute Megakaryoblastic Leukemia (M7)|Adult Acute Minimally Differentiated Myeloid Leukemia (M0)|Adult Acute Monoblastic Leukemia (M5a)|Adult Acute Monocytic Leukemia (M5b)|Adult Acute Myeloblastic Leukemia With Maturation (M2)|Adult Acute Myeloblastic Leukemia Without Maturation (M1)|Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities|Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)|Adult Acute Myeloid Leukemia With t(15;17)(q22;q12)|Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)|Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)|Adult Acute Myelomonocytic Leukemia (M4)|Adult Acute Promyelocytic Leukemia (M3)|Adult Erythroleukemia (M6a)|Adult Pure Erythroid Leukemia (M6b)|Blastic Phase Chronic Myelogenous Leukemia|Myelodysplastic/Myeloproliferative Neoplasms|Previously Treated Myelodysplastic Syndromes|Recurrent Adult Acute Lymphoblastic Leukemia|Recurrent Adult Acute Myeloid Leukemia|Relapsing Chronic Myelogenous Leukemia|Secondary Acute Myeloid Leukemia|T-cell Adult Acute Lymphoblastic Leukemia|Untreated Adult Acute Lymphoblastic Leukemia|Untreated Adult Acute Myeloid Leukemia National Cancer Institute (NCI) December 2005 Phase 1
NCT00098956 Completed Extensive Stage Small Cell Lung Cancer|Recurrent Small Cell Lung Cancer National Cancer Institute (NCI) January 2005 Phase 2
NCT00082017 Completed Lymphoma, Large-Cell, Ki-1|Lymphoma, T-Cell National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) April 2004 Phase 2
NCT00072267 Completed Fallopian Tube Cancer|Ovarian Cancer|Primary Peritoneal Cavity Cancer University Health Network, Toronto|National Cancer Institute (NCI) January 2004 Phase 2
NCT00072189 Terminated Recurrent Melanoma|Stage IV Melanoma National Cancer Institute (NCI) November 2003 Phase 2
NCT00030888 Unknown status Kidney Cancer University of California, San Francisco|National Cancer Institute (NCI) December 2002 Phase 2

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

PKC Signaling Pathway Map

Related PKC Products

Tags: buy Staurosporine | Staurosporine supplier | purchase Staurosporine | Staurosporine cost | Staurosporine manufacturer | order Staurosporine | Staurosporine distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID